{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:59:40Z","timestamp":1778626780340,"version":"3.51.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Stiftung f\u00fcr Angewandte Krebsforschung"},{"name":"Krebsliga Z\u00fcrich"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["CRSII3_147697"],"award-info":[{"award-number":["CRSII3_147697"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["PP00P3_133657"],"award-info":[{"award-number":["PP00P3_133657"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv101","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T02:17:54Z","timestamp":1425003474000},"page":"1649-1660","source":"Crossref","is-referenced-by-count":31,"title":["Searching for targets for the systemic therapy of mesothelioma"],"prefix":"10.1016","volume":"26","author":[{"given":"R.A.","family":"Stahel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Weder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Felley-Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Petrausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Schmitt-Opitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv101_bb0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1183\/09031936.00207213","article-title":"Multimodal management of malignant pleural mesothelioma: where are we today?","volume":"44","author":"Van Schil","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1093\/annonc\/mdv101_bb0020","first-page":"75","article-title":"Hippo\/YAP pathway for targeted therapy","volume":"3","author":"Felley-Bosco","year":"2014","journal-title":"Transl Lung cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0025","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1172\/JCI41402","article-title":"Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4\/6 inhibition","volume":"120","author":"Johnson","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv101_bb0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv101_bb0035","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-10-2345","article-title":"Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors","volume":"17","author":"Shapiro","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2014.06.008","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","volume":"85","author":"Krug","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0050","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","article-title":"Elucidation of a universal size-control mechanism in Drosophila and mammals","volume":"130","author":"Dong","year":"2007","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv101_bb0055","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"},{"key":"10.1093\/annonc\/mdv101_bb0060","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev"},{"key":"10.1093\/annonc\/mdv101_bb0065","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv101_bb0070","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1101\/gad.1824509","article-title":"YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation","volume":"23","author":"Fernandez","year":"2009","journal-title":"Genes Dev"},{"key":"10.1093\/annonc\/mdv101_bb0075","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1242\/dev.098079","article-title":"Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry","volume":"140","author":"Dixit","year":"2013","journal-title":"Development"},{"key":"10.1093\/annonc\/mdv101_bb0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev"},{"key":"10.1093\/annonc\/mdv101_bb0085","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv101_bb0090","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2013.12.043","article-title":"Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer","volume":"156","author":"Mori","year":"2014","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv101_bb0095","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(12)72382-1","article-title":"First-in-man, multicenter, phase I trial evaluating the safety of first-in-class therapeutic, EGFR-targeted, paclitaxel-packaged minicells","author":"Solomon","year":"2012"},{"key":"10.1093\/annonc\/mdv101_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-13-1334","article-title":"Tumor suppressor NF2\/Merlin is a microtubule stabilizer","volume":"74","author":"Smole","year":"2014","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0110","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","article-title":"Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications","volume":"25","author":"Suraokar","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0115","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv101_bb0120","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdv101_bb0125","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv101_bb0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv101_bb0135","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdv101_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7083","article-title":"WOG 0722: a phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM)","author":"Garland","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0145","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/onc.2013.280","article-title":"Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma","volume":"33","author":"Guo","year":"2014","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv101_bb0150","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1124\/dmd.112.046052","article-title":"Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human","volume":"40","author":"Salphati","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1093\/annonc\/mdv101_bb0155","article-title":"Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K\/mTOR inhibitor, administered to patients with advanced solid tumors or non-Hodgkin's lymphoma","author":"Dolly","year":"2013"},{"key":"10.1093\/annonc\/mdv101_bb0160","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv101_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PAI.0b013e31829b6fbd","article-title":"Value of calretinin immunostaining in diagnostic pathology: a review and update","volume":"22","author":"Ordonez","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1093\/annonc\/mdv101_bb0175","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/ijc.28218","article-title":"Calretinin is essential for mesothelioma cell growth\/survival in vitro: a potential new target for malignant mesothelioma therapy?","volume":"133","author":"Blum","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1093\/annonc\/mdv101_bb0185","first-page":"613","article-title":"Platelet-derived growth factor receptor immunoreactivity in mesothelioma and non-neoplastic mesothelial cells in serous effusions","volume":"39","author":"Ascoli","year":"1995","journal-title":"Acta Cytol"},{"key":"10.1093\/annonc\/mdv101_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"Konig","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1093\/annonc\/mdv101_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000029460","article-title":"Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma","volume":"67","author":"Konig","year":"2000","journal-title":"Respiration"},{"key":"10.1093\/annonc\/mdv101_bb0200","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdv101_bb0205","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/modpathol.3800159","article-title":"CD117 expression in mesothelioma","volume":"17","author":"Arber","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdv101_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdv101_bb0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/jco.2004.22.90140.7200","article-title":"A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM)","volume":"22","author":"Villano","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0225","first-page":"912","article-title":"Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma","volume":"22","author":"Millward","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0230","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0240","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0245","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00280-012-2008-6","article-title":"Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma","volume":"71","author":"Camidge","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdv101_bb0255","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0260","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0270","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0280","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0285","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0290","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0300","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III randomized, double-blind, placebo-controlled trial","author":"Krug","year":"2011"},{"key":"10.1093\/annonc\/mdv101_bb0310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1093\/annonc\/mdv101_bb0320","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0325","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0330","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0335","first-page":"15","article-title":"Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients with untreated malignant mesothelioma","volume":"28","author":"Dowell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0340","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/jco.2010.28.15_suppl.7020","article-title":"IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II\/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma","volume":"28","author":"Zalcman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","article-title":"The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents","volume":"37","author":"Siemann","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdv101_bb0350","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2121-7-17","article-title":"Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells","volume":"7","author":"Tamilarasan","year":"2006","journal-title":"BMC Cell Biol"},{"key":"10.1093\/annonc\/mdv101_bb0360","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/187221310791163026","article-title":"Pharmacological properties of thalidomide and its analogues","volume":"4","author":"De Sanctis","year":"2010","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1093\/annonc\/mdv101_bb0365","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-5002(03)91684-9","article-title":"Thalidomide alone or in combination with cisplatin\/gemcitabine in malignant pleural mesothelioma (MM); interim results from two parallel non randomized phase II studies","volume":"41","author":"Pavlakis","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0375","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0380","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0385","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdv101_bb0390","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/1078-0432.CCR-03-0611","article-title":"Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity","volume":"10","author":"Suzuki","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0395","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1165\/ajrcmb.12.5.7742009","article-title":"The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma","volume":"12","author":"Fitzpatrick","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1093\/annonc\/mdv101_bb0400","first-page":"3200","article-title":"Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo","volume":"57","author":"Marzo","year":"1997","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0405","doi-asserted-by":"crossref","first-page":"e26218","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv101_bb0410","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0415","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"},{"key":"10.1093\/annonc\/mdv101_bb0420","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdv101_bb0425","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0","article-title":"Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)","volume":"92","author":"Parra","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0430","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1093\/annonc\/mdv101_bb0435","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0440","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-10-2232","article-title":"Cytotoxic T-lymphocyte-associated antigen-4","volume":"17","author":"Salama","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0445","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0450","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv101_bb0455","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1093\/annonc\/mdv101_bb0460","doi-asserted-by":"crossref","first-page":"33123","DOI":"10.1074\/jbc.M112.381756","article-title":"Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights","volume":"287","author":"Ma","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdv101_bb0465","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0470","first-page":"1327","article-title":"Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0475","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0480","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdv101_bb0485","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine\u2014a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv101_bb0490","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0495","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0500","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdv101_bb0505","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2006.01.007","article-title":"Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma","volume":"52","author":"Powell","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0510","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0515","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.4049\/jimmunol.165.8.4298","article-title":"Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production","volume":"165","author":"Whittaker","year":"2000","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv101_bb0520","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv101_bb0525","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1093\/annonc\/mdv101_bb0530","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol Ther"},{"key":"10.1093\/annonc\/mdv101_bb0535","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0540","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv101_bb0545","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdv101_bb0550","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv101_bb0555","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdv101_bb0560","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Scherpereel","year":"2013","journal-title":"BMC Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1649\/5024769\/mdv101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:52:31Z","timestamp":1624521151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318320"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv101","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}